ArticlePloS one2013

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.

Jonathan T Sims et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.